Zoledronic acid for the treatment of osteoporosis

Claudia Gagnon, Peter R. Ebeling

Research output: Contribution to journalShort SurveyOtherpeer-review

1 Citation (Scopus)

Abstract

Zoledronic acid (Aclasta) is a major addition to the armamentarium of osteoporosis treatment, being both effective and requiring only annual intravenous infusions, therefore eliminating some of the drawbacks or inconveniences of oral bisphosphonate therapy.

Original languageEnglish
Pages (from-to)77-78
Number of pages2
JournalMedicine Today
Volume11
Issue number6
Publication statusPublished - Jun 2010
Externally publishedYes

Cite this